Duke Team Identifies Phosphoprotein Signatures That Could Predict Breast Cancer Risk

The researchers are now using the signatures in trials examining the effectiveness of several breast cancer prevention agents and working to develop a prognostic for stratifying precancer patients according to their chances of progressing to cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.